Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.38 |
| ▸ | CTSS | P25774 | 5/20 | 0.38 |
| ▸ | MMP1 | P03956 | 4/20 | 0.34 |
| ▸ | MMP3 | P08254 | 4/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21066908 | 1.00 | CTSK (0.38) | CTSKCTSSMMP1MMP3SCN9A | |
| SCHEMBL21066909 | 0.82 | MMP1 (0.45) | CTSKMMP1MMP3SCN9ASRC | |
| SCHEMBL29004598 | 0.81 | CTSK (0.35) | CTSKCTSSMMP1MMP3SCN9A | |
| SCHEMBL29004599 | 0.81 | CTSK (0.35) | CTSKCTSSMMP1MMP3SCN9A | |
| SCHEMBL21066907 | 0.79 | EPHX1 (0.40) | — | |
| SCHEMBL21066905 | 0.79 | EPHX1 (0.40) | — | |
| SCHEMBL23005327 | 0.78 | CHRM2 (0.41) | — | |
| SCHEMBL23005328 | 0.78 | CHRM2 (0.41) | — | |
| SCHEMBL13669545 | 0.69 | CTSK (0.54) | CTSKCTSS | |
| SCHEMBL1190098 | 0.68 | NR1I2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4595969-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | Temple University Of The Commonwealth System Of Higher Education (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-3509575-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | UNIV TEMPLE (US) | 2025-03-19 | — | — | EP | disclosed |
| US-11596615-B2 | Compositions and methods for treatment of insulin resistance | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210046030-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-02-18 | — | — | US | disclosed |
| US-10729670-B2 | Compositions and methods for treatment of insulin resistance | Temple University—Of The Commonwealth Systems Of Higher Education (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190192462-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596615-B2 | Compositions and methods for treatment of insulin resistance | GPR119, INSR, IAPP | CTSK 4061/4885CTSS 4343/4885MMP1 2949/4885 |
| US-10729670-B2 | Compositions and methods for treatment of insulin resistance | GPR119, INSR, IAPP | CTSK 4061/4885CTSS 4343/4885MMP1 2949/4885 |
| US-20190192462-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | GPR119, INSR, IAPP | CTSK 4061/4885CTSS 4343/4885MMP1 2949/4885 |
| US-20210046030-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | GPR119, INSR, IAPP | CTSK 4061/4885CTSS 4343/4885MMP1 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.